[
  {
    "ts": null,
    "headline": "Big pharma's multiple looming patent cliffs: What to know",
    "summary": "The pharmaceutical industry is staring down a major patent cliff, with key drugs from Merck (MRK), Bristol Myers Squibb (BMY), and Johnson & Johnson (JNJ) set to lose exclusivity by 2030. Yahoo Finance Senior Reporter Anjalee Khemlani and Freedom Capital Markets chief global strategist Jay Woods join Market Domination host Josh Lipton to discuss the industry's risks and how Wall Street is responding. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=6c19949832175d329a0625c8a4547b90492148f57fabbb3a53416d99530dda68",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752267366,
      "headline": "Big pharma's multiple looming patent cliffs: What to know",
      "id": 135885558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The pharmaceutical industry is staring down a major patent cliff, with key drugs from Merck (MRK), Bristol Myers Squibb (BMY), and Johnson & Johnson (JNJ) set to lose exclusivity by 2030. Yahoo Finance Senior Reporter Anjalee Khemlani and Freedom Capital Markets chief global strategist Jay Woods join Market Domination host Josh Lipton to discuss the industry's risks and how Wall Street is responding. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=6c19949832175d329a0625c8a4547b90492148f57fabbb3a53416d99530dda68"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Slide Friday Afternoon",
    "summary": "Health care stocks declined Friday afternoon, with the NYSE Health Care Index down 1.2% and the Heal",
    "url": "https://finnhub.io/api/news?id=d9b4d0e3fa23f42e95bc16a5bab0aeac903262f10933e8146193564b2b02f237",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752256324,
      "headline": "Sector Update: Health Care Stocks Slide Friday Afternoon",
      "id": 135883719,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Health care stocks declined Friday afternoon, with the NYSE Health Care Index down 1.2% and the Heal",
      "url": "https://finnhub.io/api/news?id=d9b4d0e3fa23f42e95bc16a5bab0aeac903262f10933e8146193564b2b02f237"
    }
  },
  {
    "ts": null,
    "headline": "Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys",
    "summary": "Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys",
    "url": "https://finnhub.io/api/news?id=f449d5ea2dfbea4cff466396007d65a11120af381c1f5fa3562ac5ac831ba067",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752254633,
      "headline": "Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys",
      "id": 135884821,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f449d5ea2dfbea4cff466396007d65a11120af381c1f5fa3562ac5ac831ba067"
    }
  },
  {
    "ts": null,
    "headline": "Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?",
    "summary": "Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finnhub.io/api/news?id=770018c08d9b9537bf3a8812904804be2149320378949cbc65db51b811be2e9f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752250202,
      "headline": "Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?",
      "id": 135883720,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=770018c08d9b9537bf3a8812904804be2149320378949cbc65db51b811be2e9f"
    }
  },
  {
    "ts": null,
    "headline": "MRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric Patients",
    "summary": "Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to 11 years.",
    "url": "https://finnhub.io/api/news?id=1bec716b39a5f053e53fb340bae1574a4612fa5e92fce64bf9232873b785a658",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752245880,
      "headline": "MRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric Patients",
      "id": 135883721,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to 11 years.",
      "url": "https://finnhub.io/api/news?id=1bec716b39a5f053e53fb340bae1574a4612fa5e92fce64bf9232873b785a658"
    }
  },
  {
    "ts": null,
    "headline": "Adrenal Crisis Market Analysis and Forecast Report 2025-2035 with Competitive Benchmarking of Eton Pharmaceuticals, Antares Pharma, and Pfizer",
    "summary": "The global adrenal crisis market is witnessing significant growth driven by increasing adrenal insufficiency recognition and rising adrenal crisis incidents. The expanding global prevalence of autoimmune diseases and corticosteroid use for chronic conditions further accelerates market demand. However, challenges such as high treatment costs, limited awareness in low-income regions, and diagnostic complexities may slow adoption in emerging markets. Between 2025-2035, advancements in diagnostic te",
    "url": "https://finnhub.io/api/news?id=577299c099dd514bd7f385e2fb2ed2e1f44b2173791698ac6fd10ca4291a9e4c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752242700,
      "headline": "Adrenal Crisis Market Analysis and Forecast Report 2025-2035 with Competitive Benchmarking of Eton Pharmaceuticals, Antares Pharma, and Pfizer",
      "id": 135883722,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The global adrenal crisis market is witnessing significant growth driven by increasing adrenal insufficiency recognition and rising adrenal crisis incidents. The expanding global prevalence of autoimmune diseases and corticosteroid use for chronic conditions further accelerates market demand. However, challenges such as high treatment costs, limited awareness in low-income regions, and diagnostic complexities may slow adoption in emerging markets. Between 2025-2035, advancements in diagnostic te",
      "url": "https://finnhub.io/api/news?id=577299c099dd514bd7f385e2fb2ed2e1f44b2173791698ac6fd10ca4291a9e4c"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer and Astellas’ Xtandi improves OS as combination therapy",
    "summary": "While there was a positive trend in the monotherapy cohort, there was no statistical improvement in OS.",
    "url": "https://finnhub.io/api/news?id=fbfa33574b4101f0129ff8ba6da7e2f617dea924e88b24d2b118e13f21aef02b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752233265,
      "headline": "Pfizer and Astellas’ Xtandi improves OS as combination therapy",
      "id": 135883723,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "While there was a positive trend in the monotherapy cohort, there was no statistical improvement in OS.",
      "url": "https://finnhub.io/api/news?id=fbfa33574b4101f0129ff8ba6da7e2f617dea924e88b24d2b118e13f21aef02b"
    }
  },
  {
    "ts": null,
    "headline": "Functional Dyspepsia Market Analysis and Forecast, 2025-2035, Competitive Analysis of AstraZeneca, P&G, Takeda, Prestige Consumer Healthcare, Kenvue Brands, Dr. Reddy's, Pfizer, ZERIA, Daewoong",
    "summary": "Functional dyspepsia, marked by untraceable upper abdominal discomfort, is seeing innovation through pharmacological treatments, lifestyle changes, and alternative therapies like herbal and microbiome modulation. Investment in digital health and GI research is boosting symptom management, while refined diagnostic criteria aid identification. Challenges such as symptom overlap and treatment limitations persist, yet AI-driven patient solutions are promising. North America leads the market due to a",
    "url": "https://finnhub.io/api/news?id=36ac6442334db3f149c0228fac6b5d950b19662ae2f1086e8f0d2e4aeb53b4c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752222060,
      "headline": "Functional Dyspepsia Market Analysis and Forecast, 2025-2035, Competitive Analysis of AstraZeneca, P&G, Takeda, Prestige Consumer Healthcare, Kenvue Brands, Dr. Reddy's, Pfizer, ZERIA, Daewoong",
      "id": 135874539,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Functional dyspepsia, marked by untraceable upper abdominal discomfort, is seeing innovation through pharmacological treatments, lifestyle changes, and alternative therapies like herbal and microbiome modulation. Investment in digital health and GI research is boosting symptom management, while refined diagnostic criteria aid identification. Challenges such as symptom overlap and treatment limitations persist, yet AI-driven patient solutions are promising. North America leads the market due to a",
      "url": "https://finnhub.io/api/news?id=36ac6442334db3f149c0228fac6b5d950b19662ae2f1086e8f0d2e4aeb53b4c7"
    }
  },
  {
    "ts": null,
    "headline": "Burns Market Analysis and Forecast Report 2025-2035 Featuring Pfizer, Perrigo, Kenvue Brands, 3M, Smith+Nephew, Molnlycke, Cardinal Health, Convatec, Haleon, Coloplast, DeRoyal Industries",
    "summary": "The global burns market is experiencing significant growth, fueled by rising burn incidences and enhanced awareness of wound care. Increased occurrences of road accidents and industrial mishaps have propelled the demand for comprehensive treatment solutions, including pharmacological therapies and advanced dressings. Innovations in regenerative medicine and digital health platforms are reshaping burn care, improving patient outcomes. Key market players are focusing on R&D and strategic partnersh",
    "url": "https://finnhub.io/api/news?id=53cd5cf322cfef0cc27d6ec12ae0e63863a04a4f3e8222f91a13184ab64376f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752221940,
      "headline": "Burns Market Analysis and Forecast Report 2025-2035 Featuring Pfizer, Perrigo, Kenvue Brands, 3M, Smith+Nephew, Molnlycke, Cardinal Health, Convatec, Haleon, Coloplast, DeRoyal Industries",
      "id": 135873347,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The global burns market is experiencing significant growth, fueled by rising burn incidences and enhanced awareness of wound care. Increased occurrences of road accidents and industrial mishaps have propelled the demand for comprehensive treatment solutions, including pharmacological therapies and advanced dressings. Innovations in regenerative medicine and digital health platforms are reshaping burn care, improving patient outcomes. Key market players are focusing on R&D and strategic partnersh",
      "url": "https://finnhub.io/api/news?id=53cd5cf322cfef0cc27d6ec12ae0e63863a04a4f3e8222f91a13184ab64376f4"
    }
  },
  {
    "ts": null,
    "headline": "Chlamydia Market Analysis and Forecast, 2025-2035 Featuring ActivBiotics, Bausch Health, Allergan, WCG Clinical, Hologic, Evofem, CRMI, Meridian Bioscience, Pfizer",
    "summary": "The global chlamydia market is projected for significant growth driven by rising chlamydia infections, with 127 million new cases annually, as per the World Health Organization. Key factors boosting the market include the adoption of advanced diagnostics like Nucleic Acid Amplification Tests (NAATs) and Point-of-Care Testing (POCT), alongside public health initiatives increasing awareness and screening. Challenges such as asymptomatic cases, social stigma, and antibiotic resistance persist, but",
    "url": "https://finnhub.io/api/news?id=d300f678f8e97ab13bc337dc9670e5860da1f892d5a59ee4841a8546fd357344",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752221220,
      "headline": "Chlamydia Market Analysis and Forecast, 2025-2035 Featuring ActivBiotics, Bausch Health, Allergan, WCG Clinical, Hologic, Evofem, CRMI, Meridian Bioscience, Pfizer",
      "id": 135879866,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The global chlamydia market is projected for significant growth driven by rising chlamydia infections, with 127 million new cases annually, as per the World Health Organization. Key factors boosting the market include the adoption of advanced diagnostics like Nucleic Acid Amplification Tests (NAATs) and Point-of-Care Testing (POCT), alongside public health initiatives increasing awareness and screening. Challenges such as asymptomatic cases, social stigma, and antibiotic resistance persist, but",
      "url": "https://finnhub.io/api/news?id=d300f678f8e97ab13bc337dc9670e5860da1f892d5a59ee4841a8546fd357344"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: conclusive trial in prostate cancer",
    "summary": "Pfizer announces that the Phase 3 study conducted with Astellas has shown that Xtandi in combination with leuprolide significantly prolonged overall survival in men with high-risk, non-metastatic...",
    "url": "https://finnhub.io/api/news?id=66d0e66d0e9e5fb3d87637276d78ad00488b7b1ba5ee078a61a9fe6f8b81111a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752221136,
      "headline": "Pfizer: conclusive trial in prostate cancer",
      "id": 135875207,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer announces that the Phase 3 study conducted with Astellas has shown that Xtandi in combination with leuprolide significantly prolonged overall survival in men with high-risk, non-metastatic...",
      "url": "https://finnhub.io/api/news?id=66d0e66d0e9e5fb3d87637276d78ad00488b7b1ba5ee078a61a9fe6f8b81111a"
    }
  },
  {
    "ts": null,
    "headline": "Psoriatic Arthritis Market Report 2025-2035 | Competitive Analysis of AbbVie, UCB, Pfizer, Johnson & Johnson, Eli Lilly and Co, Bristol-Myers Squibb, Affibody, Amgen, Boehringer Ingelheim, Sun Pharma",
    "summary": "Psoriatic arthritis is a chronic inflammatory disease linked to psoriasis, characterized by joint inflammation, pain, and swelling. Affecting both men and women, typically between ages 30-50, it's driven by rising autoimmune diseases and emerging biologic treatments like TNF and JAK inhibitors. Key market developments include advances in early diagnosis tools and precision medicine, tailoring treatments to genetic profiles. While growth is challenged by high biologic costs and diagnosis complexi",
    "url": "https://finnhub.io/api/news?id=6d6c2f9bc2075c0b32e4585440d25a0af4a43c7f00592f693f00f0d680f64571",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752220860,
      "headline": "Psoriatic Arthritis Market Report 2025-2035 | Competitive Analysis of AbbVie, UCB, Pfizer, Johnson & Johnson, Eli Lilly and Co, Bristol-Myers Squibb, Affibody, Amgen, Boehringer Ingelheim, Sun Pharma",
      "id": 135876885,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Psoriatic arthritis is a chronic inflammatory disease linked to psoriasis, characterized by joint inflammation, pain, and swelling. Affecting both men and women, typically between ages 30-50, it's driven by rising autoimmune diseases and emerging biologic treatments like TNF and JAK inhibitors. Key market developments include advances in early diagnosis tools and precision medicine, tailoring treatments to genetic profiles. While growth is challenged by high biologic costs and diagnosis complexi",
      "url": "https://finnhub.io/api/news?id=6d6c2f9bc2075c0b32e4585440d25a0af4a43c7f00592f693f00f0d680f64571"
    }
  }
]